Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081796 · ClinicalTrials.gov registry record · Phase 3
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 438
- Enrollment target
NCT00081796: Completed Phase 3 study, sponsored by Sanofi.
NCT00081796 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 438 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00081796, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 438 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to determine if RPR109881 is a better treatment than capecitabine (Xeloda) for advanced breast cancer in patients that no longer benefit from docetaxel and/or paclitaxel.
Interventions
- DRUG capecitabine
- DRUG larotaxel (RPR109881, XRP9881)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00081796 record still lists
NCT00081796 is an interventional study that assigns participants to a tested intervention. The registered 438 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which capecitabine is the first listed.
NCT00081796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00081796 about?
NCT00081796 is a clinical study titled "Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer". The purpose of this clinical trial is to determine if RPR109881 is a better treatment than capecitabine (Xeloda) for advanced breast cancer in patients that no longer benefit from docetaxel and/or paclitaxel.
What is the current status of trial NCT00081796?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 438 participants. The study started on 2004-04. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00081796?
The interventions under investigation include: capecitabine (DRUG), larotaxel (RPR109881, XRP9881) (DRUG).
Who is sponsoring clinical trial NCT00081796?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00081796's enrollment target sits among peer trials
438 874th of 2000 higher than 1,127 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT05421663 · 439 participants · Phase 1
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT06235151 · 439 participants · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia